select a format

Single User License
USD 2000 INR 128580
Site License
USD 4000 INR 257160
Corporate User License
USD 6000 INR 385740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Gaucher Disease Type III-Pipeline Review, H2 2016

Gaucher Disease Type III-Pipeline Review, H2 2016


  • Products Id :- GMDHC8885IDB
  • |
  • Pages: 36
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Gaucher Disease Type III-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease Type III-Pipeline Review, H2 2016, provides an overview of the Gaucher Disease Type III (Genetic Disorders) pipeline landscape.

Gaucher disease type III also known as chronic neuronopathic Gaucher disease (subacute form of neuronopathic Gaucher disease). Symptoms include mental deterioration, ataxia, and myoclonic seizures. The cause of Gaucher disease III is the accumulation of a fatty material called glucocerebroside (also known as glucosylceramide) Treatment includes enzyme replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease Type III-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gaucher Disease Type III (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gaucher Disease Type III (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease Type III and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 1 respectively.

Gaucher Disease Type III (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease Type III (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Gaucher Disease Type III (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gaucher Disease Type III (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gaucher Disease Type III (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease Type III (Genetic Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gaucher Disease Type III (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gaucher Disease Type III (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gaucher Disease Type III Overview 6

Therapeutics Development 7

Pipeline Products for Gaucher Disease Type III-Overview 7

Gaucher Disease Type III-Therapeutics under Development by Companies 8

Gaucher Disease Type III-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Gaucher Disease Type III-Products under Development by Companies 11

Gaucher Disease Type III-Companies Involved in Therapeutics Development 12

Actelion Ltd 12

Belrose Pharma Inc 13

Erad Therapeutics Inc 14

Genzyme Corp 15

Shire Plc 16

Gaucher Disease Type III-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

ambroxol-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ibiglustat-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

miglustat-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Recombinant Protein for Type I and Type III Gaucher's Disease-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

velaglucerase alfa-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Gaucher Disease Type III-Dormant Projects 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Figures

Number of Products under Development for Gaucher Disease Type III, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

List of Tables

Number of Products under Development for Gaucher Disease Type III, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Gaucher Disease Type III-Pipeline by Actelion Ltd, H2 2016 12

Gaucher Disease Type III-Pipeline by Belrose Pharma Inc, H2 2016 13

Gaucher Disease Type III-Pipeline by Erad Therapeutics Inc, H2 2016 14

Gaucher Disease Type III-Pipeline by Genzyme Corp, H2 2016 15

Gaucher Disease Type III-Pipeline by Shire Plc, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Gaucher Disease Type III-Dormant Projects, H2 2016 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actelion Ltd, Belrose Pharma Inc, Erad Therapeutics Inc, Genzyme Corp, Shire Plc

Gaucher Disease Type III Therapeutic Products under Development, Key Players in Gaucher Disease Type III Therapeutics, Gaucher Disease Type III Pipeline Overview, Gaucher Disease Type III Pipeline, Gaucher Disease Type III Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com